ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0526

Using Autoencoders for Imputing Missing Data in eGFR Decline Trajectories of Patients with CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Zamanzadeh, Davina J., University of California Los Angeles, Los Angeles, California, United States
  • Petousis, Panayiotis, University of California Los Angeles, Los Angeles, California, United States
  • Davis, Tyler Austin, University of California Los Angeles, Los Angeles, California, United States
  • Garlid, Anders Olav, University of California Los Angeles, Los Angeles, California, United States
  • Wang, Xiaoyan, University of California Los Angeles, Los Angeles, California, United States
  • Norris, Keith C., University of California Los Angeles, Los Angeles, California, United States
  • Duru, Obidiugwu, University of California Los Angeles, Los Angeles, California, United States
  • Tuttle, Katherine R., Providence St Joseph Health, Spokane, Washington, United States
  • Bui, Alex, University of California Los Angeles, Los Angeles, California, United States
  • Nicholas, Susanne B., University of California Los Angeles, Los Angeles, California, United States

Group or Team Name

  • CURE-CKD Registry Study Team
Background

Using machine learning (ML) approaches to impute missing data has not been explored in CKD progression. We investigated the utility of a data-driven imputation to improve downstream classifier prediction of rapid eGFR decline in the CURE-CKD registry.

Methods

We analyzed CKD patients at UCLA (N=13,206) over a 2-year period. We used: 1) the dataset with missing data; and 2) a censored subset with no missing data. We introduced 33% and 66% missingness by removing values by removing values either missing completely at random (MCAR); missing at random (MAR); or missing not at random (MNAR). We included: eGFR, hemoglobin (HbA1c), systolic blood pressure (SBP), number of ambulatory and inpatient visits, age, sex, ethnicity, rurality status, diagnosis of hypertension, diabetes mellitus (DM), pre-DM, and use of renin angiotensin aldosterone system inhibitors. We introduced missingness on SBP and HbA1c to mirror the original dataset. We imputed missing values using an autoencoder ML model. To predict a 40% eGFR decline over 2 years, we developed random forest models using the full and resultant imputed datasets.

Results

On the full subset, the MNAR imputation method achieved a root mean squared error (RMSE) of 0. The MAR method achieved RMSE of 3.8 at 33% missingness and 5.4 at 66%. MCAR achieved RMSE of 38.5 at 33% missingness and 56.4 at 66%. Using the random forest model to predict rapid decline on the fully observed subset without removing and imputing data achieved a receiver operating characteristic (ROC) area under the curve (AUC) mean of 80.8%±1.1 and precision/recall (PR)-AUC mean of 23.9%±1.5; the same as our methodology on MNAR, which is explained by the RMSE of 0, shown in Table 1.

Conclusion

Our method accurately imputes clinical data values while accounting for uncertainty caused by missing values.

MethodMean ROC-AUC
Missingness 66% / 33%
Mean PR-AUC
Missingness 66% / 33%
MNAR80.8±1.1 / 80.8±1.123.9±1.5 / 23.9±1.5
MAR69.1±1.3 / 74.2±0.922.3±1.5 / 23.3±1.8
MCAR70.6±0.9 / 69.5±0.99.3±0.6 / 10.9±0.6

Funding

  • Other NIH Support